Clovis Oncology, Inc. (CLVS) Position Raised by Cornerstone Capital Management Holdings LLC.

Cornerstone Capital Management Holdings LLC. raised its stake in shares of Clovis Oncology, Inc. (NASDAQ:CLVS) by 1,362.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,544 shares of the biopharmaceutical company’s stock after buying an additional 16,344 shares during the period. Cornerstone Capital Management Holdings LLC.’s holdings in Clovis Oncology were worth $1,116,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. raised its position in Clovis Oncology by 20.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,400 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the last quarter. First Mercantile Trust Co. purchased a new position in shares of Clovis Oncology during the first quarter worth approximately $115,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Clovis Oncology by 71.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 758 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Clovis Oncology during the first quarter worth approximately $185,000. Finally, Ameritas Investment Partners Inc. purchased a new position in shares of Clovis Oncology during the first quarter worth approximately $195,000. Institutional investors and hedge funds own 97.55% of the company’s stock.

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology, Inc. (NASDAQ:CLVS) traded up 4.69% during midday trading on Tuesday, hitting $92.00. 1,072,415 shares of the stock traded hands. The stock’s market cap is $4.12 billion. Clovis Oncology, Inc. has a 1-year low of $11.57 and a 1-year high of $92.00. The company has a 50-day moving average of $55.32 and a 200-day moving average of $55.82. Clovis Oncology also was the recipient of some unusual options trading activity on Monday. Stock investors acquired 11,745 put options on the company. This is an increase of 519% compared to the average daily volume of 1,898 put options.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.10. The company had revenue of $7.05 million during the quarter, compared to the consensus estimate of $6.04 million. On average, equities analysts expect that Clovis Oncology, Inc. will post ($5.31) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2655203/clovis-oncology-inc-clvs-position-raised-by-cornerstone-capital-management-holdings-llc.html.

A number of equities analysts have commented on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $79.00 price objective on shares of Clovis Oncology in a report on Tuesday. Bank of America Corporation reiterated a “buy” rating and issued a $103.00 price objective (up previously from $75.00) on shares of Clovis Oncology in a report on Tuesday. J P Morgan Chase & Co set a $72.00 price objective on shares of Clovis Oncology and gave the stock a “buy” rating in a report on Thursday, June 1st. Janney Montgomery Scott upgraded shares of Clovis Oncology from a “neutral” rating to a “buy” rating in a report on Tuesday. Finally, Leerink Swann assumed coverage on shares of Clovis Oncology in a report on Tuesday, June 13th. They issued an “outperform” rating and a $85.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $70.67.

In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction on Monday, May 15th. The shares were sold at an average price of $47.39, for a total value of $142,170.00. Following the completion of the sale, the insider now directly owns 203,583 shares of the company’s stock, valued at approximately $9,647,798.37. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 9,000 shares of company stock valued at $495,690. Insiders own 17.40% of the company’s stock.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CLVS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.